Title: A phase 1b study of BCL-XL degrader DT2216 in combination with weekly paclitaxel in recurrent platinum-resistant ovarian cancer

Brief Title: DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Brief Summary: The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: - DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) - Paclitaxel (a type of antimicrotubule agent)

Title: Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors

Brief Title: REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Brief Summary: The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials

Title: A phase 2 trial of maintenance abemaciclib/letrozole after systemic therapy in patients with advanced or recurrent estrogen receptor positive, mismatch repair proficient, TP53 wild-type endometrial cancer

Brief Title: ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Brief Summary: A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib and pembrolizumab alone following chemotherapy and pembrolizumab. The names of the study drugs involved in this study are: - Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) - Letrozole (a type of aromatase inhibitor) - Pembrolizumab (a type of monoclonal antibody)

Title: A Phase 2 Study of Dostarlimab in Combination with Cobolimab in Advanced Cervical Cancer

Brief Title: Dostarlimab and Cobolimab in Advanced Cervical Cancer

Brief Summary: This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

Title: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors

Brief Title: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Brief Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Title: RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib alone and in Combination with Metformin, Zotatifin and Gedatolisib

Brief Title: RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Brief Summary: This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: - Abemaciclib (also known as Verzenio™) - Letrozole (also known as Femara®) - Metformin (also known as Glucophage®) - Zotatifin (also known as eFT226) - Gedatolisib (also known as PF-05212384)

Title: Identification of Molecular Alterations Required in the Development of Ovarian Carcinomas

Brief Title: IDENTIFICATION OF MOLECULAR ALTERATIONS REQUIRED IN THE DEVELOPMENT OF OVARIAN CARCINOMAS